Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 8;3(6):100321.
doi: 10.1016/j.xinn.2022.100321. Epub 2022 Sep 9.

The first Chinese oral anti-COVID-19 drug Azvudine launched

Bin Yu  1 , Junbiao Chang  1   2
Affiliations

The first Chinese oral anti-COVID-19 drug Azvudine launched

Bin Yu et al. Innovation (Camb). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Mechanism of Azvudine against SARS-CoV-2
See this image and copyright information in PMC

References

    1. Chang J. 4′-Modified nucleosides for antiviral drug discovery: Achievements and perspectives. Acc. Chem. Res. 2022;55:565–578. - PubMed
    1. Sun L., Peng Y., Yu W., et al. Mechanistic insight into antiretroviral potency of 2′-deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a long-lasting effect on HIV-1 prevention. J. Med. Chem. 2020;63:8554–8566. - PubMed
    1. Yu B., Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Sig. Transduct. Target Ther. 2020;5:236. - PMC - PubMed
    1. Zhang J.L., Li Y.H., Wang L.L., et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Sig. Transduct. Target Ther. 2021;6:414. - PMC - PubMed
    1. Ren Z., Luo H., Yu Z., et al. A Randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv. Sci. 2020;7:2001435. - PMC - PubMed

LinkOut - more resources